Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Sci Rep ; 9(1): 13147, 2019 09 11.
Artículo en Inglés | MEDLINE | ID: mdl-31511534

RESUMEN

Gluten proteins are the causative agent of Celiac Disease (CD), a life-long food intolerance characterized by an autoimmune enteropathy. Inadvertent gluten exposure is frequent even in celiac patients complying with a gluten-free diet, and the supplementation of exogenous gluten-digestive enzymes (glutenases) is indeed a promising approach to reduce the risk of dietary gluten boost. Here we describe Endopeptidase 40, a novel glutenase discovered as secreted protein from the soil actinomycete Actinoallomurus A8, and its recombinant active form produced by Streptomyces lividans TK24. E40 is resistant to pepsin and trypsin, and active in the acidic pH range 3 to 6. E40 efficiently degrades the most immunogenic 33-mer as well as the whole gliadin proteins, as demonstrated by SDS-PAGE, HPLC, LC-MS/MS, and ELISA. T lymphocytes from duodenal biopsies of celiac patients showed a strongly reduced or absent release of IFN-γ when exposed to gluten digested with E40. Data in gastrointestinal simulated conditions suggest that no toxic peptides are freed during gluten digestion by E40 into the stomach to enter the small intestine, thus counteracting the intestinal inflammatory cascade to occur in CD patients. E40 is proposed as a novel candidate in Oral Enzymatic Therapy for the dietary management of gluten toxicity.


Asunto(s)
Actinobacteria/enzimología , Proteínas Bacterianas/metabolismo , Endopeptidasas/metabolismo , Intolerancia Alimentaria/metabolismo , Glútenes/metabolismo , Enfermedad Celíaca/metabolismo , Cromatografía Liquida , Ensayo de Inmunoadsorción Enzimática , Gliadina/metabolismo , Humanos , Intestino Delgado/metabolismo , Espectrometría de Masas en Tándem
2.
Nutrients ; 10(3)2018 Mar 12.
Artículo en Inglés | MEDLINE | ID: mdl-29534502

RESUMEN

We have previously reported that 60% sucrose diet-fed ChREBP knockout mice (KO) showed body weight loss resulting in lethality. We aimed to elucidate whether sucrose and fructose metabolism are impaired in KO. Wild-type mice (WT) and KO were fed a diet containing 30% sucrose with/without 0.08% miglitol, an α-glucosidase inhibitor, and these effects on phenotypes were tested. Furthermore, we compared metabolic changes of oral and peritoneal fructose injection. A thirty percent sucrose diet feeding did not affect phenotypes in KO. However, miglitol induced lethality in 30% sucrose-fed KO. Thirty percent sucrose plus miglitol diet-fed KO showed increased cecal contents, increased fecal lactate contents, increased growth of lactobacillales and Bifidobacterium and decreased growth of clostridium cluster XIVa. ChREBP gene deletion suppressed the mRNA levels of sucrose and fructose related genes. Next, oral fructose injection did not affect plasma glucose levels and liver fructose contents; however, intestinal sucrose and fructose related mRNA levels were increased only in WT. In contrast, peritoneal fructose injection increased plasma glucose levels in both mice; however, the hepatic fructose content in KO was much higher owing to decreased hepatic Khk mRNA expression. Taken together, KO showed sucrose intolerance and fructose malabsorption owing to decreased gene expression.


Asunto(s)
Azúcares de la Dieta/efectos adversos , Disbiosis/etiología , Intolerancia Alimentaria/fisiopatología , Fructosa/efectos adversos , Síndromes de Malabsorción/fisiopatología , Proteínas Nucleares/metabolismo , Sacarosa/efectos adversos , Factores de Transcripción/metabolismo , Animales , Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice , Bifidobacterium/efectos de los fármacos , Bifidobacterium/crecimiento & desarrollo , Bifidobacterium/aislamiento & purificación , Ciego/efectos de los fármacos , Ciego/metabolismo , Ciego/microbiología , Ciego/patología , Clostridium/efectos de los fármacos , Clostridium/crecimiento & desarrollo , Clostridium/aislamiento & purificación , Azúcares de la Dieta/metabolismo , Disbiosis/microbiología , Intolerancia Alimentaria/etiología , Intolerancia Alimentaria/metabolismo , Intolerancia Alimentaria/patología , Fructoquinasas/química , Fructoquinasas/genética , Fructoquinasas/metabolismo , Fructosa/administración & dosificación , Fructosa/metabolismo , Microbioma Gastrointestinal/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Inhibidores de Glicósido Hidrolasas/farmacología , Inyecciones Intraperitoneales , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/microbiología , Mucosa Intestinal/patología , Intestinos/efectos de los fármacos , Intestinos/microbiología , Intestinos/patología , Lactobacillales/efectos de los fármacos , Lactobacillales/crecimiento & desarrollo , Lactobacillales/aislamiento & purificación , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Síndromes de Malabsorción/etiología , Síndromes de Malabsorción/metabolismo , Síndromes de Malabsorción/patología , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas Nucleares/genética , Tamaño de los Órganos/efectos de los fármacos , Factores de Transcripción/genética
3.
J Med Food ; 21(3): 207-214, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29315017

RESUMEN

Nonceliac gluten sensitivity (NCGS) is a gluten-related gastrointestinal disorder distinct from celiac disease (CD) and gluten allergy that is not easy to diagnose due to the lack of biomarkers. It is characterized by intestinal symptoms and extraintestinal manifestations with the consumption of gluten-containing foods. In contrast to CD, NCGS patients do not present a genetic predisposition or intestinal villi atrophy. Recent studies question the proinflammatory triggering activity of α-gliadin fraction contained in wheat, since it has been demonstrated that the amylase-trypsin inhibitors (ATIs) exert a strong activating effect on the innate immune response. We aimed to analyze the role of ATIs in the activation of innate immunity and in the development of the symptoms characteristic of NCGS. A systematic literature search was made using databases such as MEDLINE, SciELO, Science Direct, and Scopus, with focus on key words such as "amylase-trypsin inhibitors," "wheat," "gluten," and "celiac." Many studies are available on the structure, inhibition mechanism, and immune system effects of ATIs, mainly focused on IgE-mediated reactions. Recently, with the increase of NCGS interest, has increased the literature on the capacity of ATIs contained in wheat to activate the innate immune system. Literature published to date questions the relationship between activation of the innate immune system and gluten in NCGS. ATIs may have acted as interfering contaminant of gluten and appear as potential activator of innate immunity in NCGS patients. In view of their potential impact, more interventional studies are needed to demonstrate the proinflammatory effect of ATIs.


Asunto(s)
Grano Comestible/efectos adversos , Inhibidores Enzimáticos/efectos adversos , Intolerancia Alimentaria/etiología , Glútenes/efectos adversos , Proteínas de Plantas/efectos adversos , Inhibidores de Tripsina/efectos adversos , alfa-Amilasas/antagonistas & inhibidores , Animales , Grano Comestible/química , Inhibidores Enzimáticos/análisis , Inhibidores Enzimáticos/metabolismo , Intolerancia Alimentaria/inmunología , Intolerancia Alimentaria/metabolismo , Intolerancia Alimentaria/fisiopatología , Glútenes/metabolismo , Hordeum/efectos adversos , Hordeum/química , Humanos , Inmunidad Innata , Inmunidad Mucosa , Mucosa Intestinal/enzimología , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Proteínas de Plantas/análisis , Proteínas de Plantas/metabolismo , Secale/efectos adversos , Secale/química , Receptores Toll-Like/agonistas , Receptores Toll-Like/metabolismo , Triticum/efectos adversos , Triticum/química , Inhibidores de Tripsina/análisis , Inhibidores de Tripsina/metabolismo
4.
Ann Nutr Metab ; 68 Suppl 1: 8-17, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27355647

RESUMEN

Childhood functional gastrointestinal disorders (FGIDs) affect a large number of children throughout the world. Carbohydrates (which provide the majority of calories consumed in the Western diet) have been implicated both as culprits for the etiology of symptoms and as potential therapeutic agents (e.g., fiber) in childhood FGIDs. In this review, we detail how carbohydrate malabsorption may cause gastrointestinal symptoms (e.g., bloating) via the physiologic effects of both increased osmotic activity and increased gas production from bacterial fermentation. Several factors may play a role, including: (1) the amount of carbohydrate ingested; (2) whether ingestion is accompanied by a meal or other food; (3) the rate of gastric emptying (how quickly the meal enters the small intestine); (4) small intestinal transit time (the time it takes for a meal to enter the large intestine after first entering the small intestine); (5) whether the meal contains bacteria with enzymes capable of breaking down the carbohydrate; (6) colonic bacterial adaptation to one's diet, and (7) host factors such as the presence or absence of visceral hypersensitivity. By detailing controlled and uncontrolled trials, we describe how there is a general lack of strong evidence supporting restriction of individual carbohydrates (e.g., lactose, fructose) for childhood FGIDs. We review emerging evidence suggesting that a more comprehensive restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) may be effective. Finally, we review how soluble fiber (a complex carbohydrate) supplementation via randomized controlled intervention trials in childhood functional gastrointestinal disorders has demonstrated efficacy.


Asunto(s)
Fenómenos Fisiológicos Nutricionales Infantiles , Carbohidratos de la Dieta/efectos adversos , Medicina Basada en la Evidencia , Intolerancia Alimentaria/fisiopatología , Enfermedades Gastrointestinales/etiología , Síndromes de Malabsorción/etiología , Medicina de Precisión , Dolor Abdominal/etiología , Dolor Abdominal/prevención & control , Niño , Dieta Baja en Carbohidratos , Carbohidratos de la Dieta/metabolismo , Fibras de la Dieta/uso terapéutico , Suplementos Dietéticos , Fermentación , Intolerancia Alimentaria/dietoterapia , Intolerancia Alimentaria/metabolismo , Intolerancia Alimentaria/microbiología , Enfermedades Gastrointestinales/dietoterapia , Enfermedades Gastrointestinales/microbiología , Enfermedades Gastrointestinales/fisiopatología , Microbioma Gastrointestinal , Humanos , Síndromes de Malabsorción/dietoterapia , Síndromes de Malabsorción/microbiología , Síndromes de Malabsorción/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA